Published Date: 02 Mar 2023
A group of medical researchers from Stanford University, together with colleagues from the Taiwan Biomedical Research Institute, have discovered a way to prevent or treat chronic lung disease. ...
Read Full NewsFindings from a phase 2 trial highlighted lacosamide's effectiveness and safety in treating neonatal seizures, showing significant seizure reduction and tolerability in patients.
Here's some of what is coming soon to NeurologyLive® this week.
Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.
FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.
5 Pulmonology Headlines You Missed in November 2025
Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43
Stage 5 CKD May Reverse Female Survival Advantage
1.
Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.
2.
Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?
3.
Patients with metastatic breast cancer can predict their response to HER2-targeted therapy using whole-body PET/CT.
4.
The pandemic had little impact on mental health symptoms.
5.
Vaccine elicits strong immune response in patients with pancreatic and colorectal cancer
1.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
2.
AI-Powered Case Studies in Oncology: Elevating Clinical Influence Through Real-World Data
3.
Understanding the Rare Disease: Werner Syndrome Explained
4.
From Bench to Bedside: The New Era of Lymphoma Treatment and Education
5.
Oncolytic Viruses in Breast Cancer: Unlocking Synergy with Novel Combination Therapies
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
4.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation